



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 27, 2020

Via E-mail

Tobin C. Schilke  
Chief Financial Officer  
Revance Therapeutics, Inc.  
7555 Gateway Boulevard  
Newark, California 94560

**Re: Revance Therapeutics, Inc.  
Form 10-Q for the quarterly period ended September 30, 2019  
Exhibit No. 10.1 - Amendment #1 to the Collaboration and License Agreement  
dated August 22, 2019 between Revance Therapeutics, Inc. and Mylan Ireland Ltd.  
Filed November 4, 2019  
File No. 001-36297**

Dear Mr. Schilke:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance